昂利康：获双氯芬酸钠肠溶片注册证书及沙库巴曲缬沙坦钠片补充申请批准

Core Viewpoint - The company announced the receipt of drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets, indicating a positive development in its product pipeline [1] Group 1: Product Approvals - The National Medical Products Administration issued a drug registration certificate for Diclofenac Sodium Enteric-Coated Tablets, with a specification of 25mg and a validity period until December 8, 2030, which is considered equivalent to passing the consistency evaluation [1] - The company received approval for an additional specification of 100mg for Sacubitril/Valsartan Sodium Tablets, with the approval valid until June 27, 2029 [1] Group 2: Market Impact - The new approvals will enhance the company's product lineup and specifications, but the sales of these drugs may be influenced by policy and market factors, leading to uncertainties [1]